Effect of increased blood levels of β-endorphin on perception of breathlessness

Chest

Volumn 143, Issue 5, 2013, Pages 1378-1385

  Mahler, Donald A ^a   Gifford, Alex H ^a   Waterman, Laurie A ^a   Ward, Joseph ^a   Kraemer, William J ^b   Kupchak, Brian R ^b   Harver, Andrew ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; CORTICOTROPIN; HYDROCORTISONE; KETOCONAZOLE; OPIATE RECEPTOR; PLACEBO;

AGED; ARTICLE; CENTRAL NERVOUS SYSTEM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DYSPNEA; ENDURANCE; FEMALE; HUMAN; LUNG FUNCTION TEST; MALE; OPEN STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BINDING; RESISTIVE LOAD BREATHING; RESPIRATORY TRACT PARAMETERS; STEROIDOGENESIS; VISUAL ANALOG SCALE;

EID: 84875868886     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-1541     Document Type: Article

References (36)

1. Le Merrer J, Becker JA, Befort K, Kieffer BL. Reward processing by the opioid system in the brain. Physiol Rev. 2009;89(4):1379-1412.
2. Zebraski SE, Kochenash SM, Raffa RB. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 2000;66(23):2221-2231. (Pubitemid 30256621)
3. Clement-Jones V, Besser GM. Clinical perspectives in opioid peptides. Br Med Bull. 1983;39(1):95-100. (Pubitemid 13220734)
4. Thorén P, Floras JS, Hoffmann P, Seals DR. Endorphins and exercise: physiological mechanisms and clinical implications. Med Sci Sports Exerc. 1990;22(4):417-428. (Pubitemid 20241706)
5. Sehgal N, Smith HS, Manchikanti L. Peripherally acting opioids and clinical implications for pain control. Pain Physician. 2011;14(3):249-258.
6. Stein C, Lang LJ. Peripheral mechanisms of opioid analgesia. Curr Opin Pharmacol. 2009;9(1):3-8.
7. Hughes J, Kosterlitz HW, Smith TW. The distribution of methionine-enkephalin and leucine-enkephalin in the brain and peripheral tissues. 1977. Br J Pharmacol. 1997;120(suppl 4):428-436. (Pubitemid 127732620)
8. Millan MJ. Multiple opioid systems and pain. Pain. 1986;27(3):303-347. (Pubitemid 17226872)
9. Mahler DA, Murray JA, Waterman LA, et al. Endogenous opioids modify dyspnoea during treadmill exercise in patients with COPD. Eur Respir J. 2009;33(4):771-777.
10. Gifford AH, Mahler DA, Waterman LA, et al. Neuromodulatory effect of endogenous opioids on the intensity and unpleasantness of breathlessness during resistive load breathing in COPD. COPD. 2011;8(3):160-166.
11. Foley KM, Kourides IA, Inturrisi CE, et al. beta-Endorphin: analgesic and hormonal effects in humans. Proc Natl Acad Sci U S A. 1979;76(10):5377-5381. (Pubitemid 10231635)
12. Sadigh B, Berglund M, Fillingim RB, Sheps D, Sylvén C. beta-Endorphin modulates adenosine provoked chest pain in men, but not in women-a comparison between patients with ischemic heart disease and healthy volunteers. Clin J Pain. 2007;23(9):750-755. (Pubitemid 351339409)
13. Loose DS, Kan PB, Hirst MA, Marcus RA, Feldman D. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest. 1983;71(5):1495-1499. (Pubitemid 13098940)
14. Engelhardt D, Dörr G, Jaspers C, Knorr D. Ketoconazole blocks cortisol secretion in man by inhibition of adrenal 11 beta-hydroxylase. Klin Wochenschr. 1985;63(13):607-612. (Pubitemid 15039601)
15. Jarmukli NF, Ahn J, Iranmanesh A, Russell DC. Effect of raised plasma beta endorphin concentrations on peripheral pain and angina thresholds in patients with stable angina. Heart. 1999;82(2):204-209. (Pubitemid 29362872)
16. Doi A, Ramirez JM. Neuromodulation and the orchestration of the respiratory rhythm. Respir Physiol Neurobiol. 2008;164(1-2):96-104.
17. Kudlacz EM, Logan DE, Shatzer SA, Farrell AM, Baugh LE. Tachykinin-mediated respiratory effects in conscious guinea pigs: modulation by NK1 and NK2 receptor antagonists. Eur J Pharmacol. 1993;241(1):17-25. (Pubitemid 23268331)
18. Tomaki M, Ichinose M, Miura M, et al. Elevated substance P content in induced sputum from patients with asthma and patients with chronic bronchitis. Am J Respir Crit Care Med. 1995;151(3 pt 1):613-617.
19. Rabe KF, Hurd S, Anzueto A, et al Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555. (Pubitemid 47403272)
20. Miller MR, Crapo R, Hankinson J, et al ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005;26(1):153-161. (Pubitemid 40945944)
21. Mahler DA, Waterman LA, Ward J, McCusker C, ZuWallack R, Baird JC. Validity and responsiveness of the self-administered computerized versions of the baseline and transition dyspnea indexes. Chest. 2007;132(4):1283-1290. (Pubitemid 47621005)
22. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179-187. (Pubitemid 29036522)
23. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720-735. (Pubitemid 41448672)
24. Gaensler EA, Smith AA. Attachment for automated single breath diffusing capacity measurement. Chest. 1973;63(2):136-145.
25. Porstmann T, Kiessig ST. Enzyme immunoassay techniques. An overview. J Immunol Methods. 1992;150(1-2):5-21.
26. Avrameas S. Amplification systems in immunoenzymatic techniques. J Immunol Methods. 1992;150(1-2):23-32.
27. Kraemer WJ, Patton JF, Knuttgen HG, et al. Hypothalamic-pituitary-adrenal responses to short-duration high-intensity cycle exercise. J Appl Physiol. 1989;66(1):161-166. (Pubitemid 19056071)
28. Pepin V, Saey D, Whittom F, LeBlanc P, Maltais F. Walking versus cycling: sensitivity to bronchodilation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(12):1517-1522. (Pubitemid 43076539)
29. Mahler DA, Ward J, Fierro-Carrion G, et al. Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD. 2004;1(2):165-172.
30. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and tox ic ity of high-dose ketoconazole. Antimicrob Agents Chemother. 1987;31(12):1874-1878. (Pubitemid 18009552)
31. Jensen D, Alsuhail A, Viola R, Dudgeon DJ, Webb KA, O'Donnell DE. Inhaled fentanyl citrate improves exercise endurance during high-intensity constant work rate cycle exercise in chronic obstructive pulmonary disease. J Pain Symptom Manage. 2012;43(4):706-719.
32. Noseda A, Carpiaux JP, Markstein C, Meyvaert A, de Maertelaer V. Disabling dyspnoea in patients with advanced disease: lack of effect of nebulized morphine. Eur Respir J. 1997;10(5):1079-1083. (Pubitemid 27201813)
33. Eaton B, Hall J, MacDonald S. Does nebulized morphine offer symptom relief to patients with disabling dyspnea during end-stage disease? Can Fam Physician. 1999;45:319-320. (Pubitemid 29136004)
34. Quartara L, Maggi CA. The tachykinin NK1 receptor. Part II: distribution and pathophysiological roles. Neuropeptides. 1998;32(1):1-49. (Pubitemid 28167857)
35. Solway J, Leff AR. Sensory neuropeptides and airway function. J Appl Physiol. 1991;71(6):2077-2087.
36. Mahler DA, Rosiello RA, Harver A, Lentine T, McGovern JF, Daubenspeck JA. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis. 1987;135(6):1229-1233. (Pubitemid 18021513)